DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule (DISCERN-FN7)

  • STATUS
    Recruiting
  • End date
    Dec 22, 2024
  • participants needed
    1480
  • sponsor
    University Hospital, Lille
Updated on 22 April 2022

Summary

Febrile neutropenia (NF) is the leading cause of unscheduled hospitalization in children with cancer. Management classically involves emergency admission to hospital for intravenous antibiotic treatment until resolution of fever and neutropenia. However, children with NF are a heterogeneous group with varying risks of severe infection (10-29%). This approach, which is recognized as excessive for low-risk episodes of severe infection, particularly in terms of quality of life and cost, is no longer recommended. Management should move to a more personalized model that takes into account the individual probability of severe infection. Clinical decision rules (CDRs) have been proposed to facilitate risk stratification, but none are useful in our French population because of insufficient reproducibility or effectiveness.

Details
Condition Neutropenia, Febrile
Treatment The Clinical Decision Rule
Clinical Study IdentifierNCT04938206
SponsorUniversity Hospital, Lille
Last Modified on22 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Followed for hemopathy or cancer
Presenting with post-chemotherapy NF
With social security coverage
With parents able to provide appropriate home supervision
Consent of parents and child if able to give consent

Exclusion Criteria

NF to diagnosis of tumor disease
Child with palliative care
Child who has had an allogeneic hematopoietic stem cell transplant within the past year
NF immediately following an autologous hematopoietic stem cell transplant
Participation in the study during a previous NF
Curative antibiotic therapy or documented infection prior to admission
Initial management at a non-investigative center
Refusal of the child or parents to participate
Translated with [www.DeepL.com/Translator](http://www.DeepL.com/Translator)
(free version)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note